Poolbeg Pharma (LON:POLB) Receives House Stock Rating from Shore Capital Group

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating reaffirmed by equities researchers at Shore Capital Group in a research note issued to investors on Tuesday,Digital Look reports.

Poolbeg Pharma Stock Performance

LON POLB opened at GBX 5.56 on Tuesday. Poolbeg Pharma has a fifty-two week low of GBX 2.40 and a fifty-two week high of GBX 5.80. The stock has a 50 day simple moving average of GBX 4.44 and a two-hundred day simple moving average of GBX 4.28. The stock has a market cap of £39.17 million, a P/E ratio of -5.91 and a beta of 1.78.

Poolbeg Pharma (LON:POLB) last released its quarterly earnings data on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. Sell-side analysts predict that Poolbeg Pharma will post -0.68 earnings per share for the current year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.